Close Menu

Genomics stocks closed sharply lower on Wednesday as the biotech sector tumbled for a second day due to profit-taking following the long holiday weekend, analysts said.

Celera Genomics (NYSE: CRA) closed at 100 7/16, down 4 1/16, or 3.9 percent, following a 7 percent drop on Tuesday. Incyte Genomics (Nasdaq: INCY) ended the session down 2 1/16, or 5.4 percent, at 36 1/2 following a 4.2 percent decline the previous day. And Affymetrix (Nasdaq: AFFX) shed 4 15/16, or 6.6 percent, to close at 70 on the heels of a 5.1 percent decline on Tuesday.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Nature News reports that researchers in Japan hope to soon test the use of reprogrammed stem cells to treat damaged corneas.

A new approach may help limit the number of fish that are mislabeled at markets or restaurants, according to New Scientist.

At Slate, the R Street Institute's Nila Bala discusses the privacy rights of suspects that genetic genealogy approaches in law enforcement bring up.

In PNAS this week: numerous mobile genetic elements contribute to Vibrio cholerae drug resistance, troponin I mutations in sudden infant deaths, and more.